Skip to main content

Table 6 Pharmacological treatment of IPF in the years 2002 – 2016a

From: Effect of smoking and comorbidities on survival in idiopathic pulmonary fibrosis

Medication N / %
No medication 42 / 31.8
Total
 Corticosteroids 75 / 56.8
 Azathioprine 28 / 37.2
 N-acetylcysteine 30 / 40.0
 Cyclophosphamide 16 / 12.1
 Pirfenidone 6 / 4.5
 Nintedanib 3 / 2.3
 Mycophenolate mofetil 1 / 0.8
Single medication
 Corticosteroids 24 / 18.2
 N-acetylcysteine 11 / 8.3
 Pirfenidone 5 /3.8
 Nintedanib 1 /0.8
 Triple therapy b 7 /5.3
Combined with prednisone as only medication
 Azathioprine 14 / 10.6
 N-acetylcysteine 13 / 9.8
 Cyclophosphamide 8 / 6.1
After prednisone therapy
 Nintedanib 2 /1.5
Before triple therapy
 Cyclophosphamide + Corticosteroids 2 / 1.5
After triple therapy
 Pirfenidone 1 / 0.8
 Cyclophosphamide 3 / 2.3
 Mycophenolate 1 / 0.8
  1. aDiagnosis of IPF between years 2002 – 2012, while the follow-up information of medication was gathered until 16.10.2016. Reimbursement (by KELA) in Finland for pirfenidone in 1st June 2013 and for nintedanib in 1st December 2015.
  2. bTriple therapy = azathioprine, N-acetylcysteine and prednisone